Joyonna Gamble-George, Ph.D.

2007-2009 VA Bay Pines Healthcare System 
 2007-2009 University of South Florida, Tampa, FL, United States 
 2009-2011 Meharry Medical College, Nashville, TN, United States 
 2011-2016 Vanderbilt University, Nashville, TN 
 2016-2018 University of Florida College of Medicine/McKnight Brain Institute 
 2019-2021 National Institutes of Health, Bethesda, MD 
"Joyonna Gamble-George"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Gamble-George JC, Longenecker CT, Webel AR, et al. (2020) ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research. Progress in Cardiovascular Diseases. 63: 79-91
Miller DR, Shaerzadeh F, Phan L, et al. (2018) HIV-1 Tat regulation of dopamine transmission and microglial reactivity is brain region specific. Glia
Gaskill PJ, Miller DR, Gamble-George J, et al. (2017) HIV, Tat and dopamine transmission. Neurobiology of Disease. 105: 51-73
Gamble-George JC, Baldi R, Halladay L, et al. (2016) Cyclooxygenase-2 inhibition reduces stress-induced affective pathology. Elife. 5
Butler B, Gamble-George J, Prins P, et al. (2014) Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice. Journal of Addiction & Prevention. 2
Bluett RJ, Gamble-George JC, Hermanson DJ, et al. (2014) Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Translational Psychiatry. 4: e408
Hermanson DJ, Gamble-George JC, Marnett LJ, et al. (2014) Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends in Pharmacological Sciences. 35: 358-67
Ramikie TS, Nyilas R, Bluett RJ, et al. (2014) Multiple mechanistically distinct modes of endocannabinoid mobilization at central amygdala glutamatergic synapses. Neuron. 81: 1111-25
Hermanson DJ, Hartley ND, Gamble-George J, et al. (2013) Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nature Neuroscience. 16: 1291-8
Gamble-George JC, Conger JR, Hartley ND, et al. (2013) Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology. 228: 401-9
See more...